Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03869684 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration
A Phase 2 study, sponsored by Senju Pharmaceutical Co..
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT03869684 is a Phase 2 study that was terminated before completion, run by Senju Pharmaceutical Co.. The registered enrollment target is 13 participants.
The verdict
NCT03869684, a Phase 2 study, was terminated before completion, sponsored by Senju Pharmaceutical Co..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
Age-related macular degeneration (AMD) is the leading cause of blindness among adults in North America. The current standard of care for patients with exudative ("wet") AMD is anti-vascular endothelial growth factor (anti-VEGF) therapy which must be administered by an injection into the eye every 4-8 weeks. MT-0814 is being developed for the treatment of patients with exudative AMD, and could offer an alternative, safer and less burdensome therapy.
Interventions
- DRUG Placebo
- DRUG MT-0814
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2019-02-25 |
| Est. Completion | 2020-04-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03869684
The ClinicalTrials.gov registry entry for NCT03869684 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Senju Pharmaceutical Co., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03869684 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03869684 about?
NCT03869684 is a clinical study titled "A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration". Age-related macular degeneration (AMD) is the leading cause of blindness among adults in North America. The current standard of care for patients with exudative ("wet") AMD is anti-vascular endothelial growth factor (anti-VEGF) therapy which must be administered by an injection into the eye every 4-...
What is the current status of trial NCT03869684?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2019-02-25. Estimated completion is 2020-04-24.
What interventions are being tested in trial NCT03869684?
The interventions under investigation include: Placebo (DRUG), MT-0814 (DRUG).
Who is sponsoring clinical trial NCT03869684?
This trial is sponsored by Senju Pharmaceutical Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.